New hope for Hard-to-Treat skin cancer: PTX-100 enters phase 2 trial
Disease control
Recruiting now
This phase 2 trial tests a drug called PTX-100 in 115 adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. Participants receive PTX-100 by IV infusion over several cycles. The goal is to see if the drug can shrink or eliminate tumors an…
Phase: PHASE2 • Sponsor: Prescient Therapeutics, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC